Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07457281) titled 'GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study' on March 3.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: West China Hospital
Condition:
Head and Neck Squamous Cell Carcinoma HNSCC
Intervention:
Drug: GV20-0251
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: April 1, 2026
Target Sample Size: 9
Countries of Recruitment:
China
To know more, visit https://clinicaltrial...